Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells

• Главные авторы: Yuelong Jiang (Автор), Long Liu (Автор), Yirong Jiang (Автор), Zhifeng Li (Автор), Liying Feng (Автор), Xinguo Zhuang (Автор), Zhijuan Lin (Автор), Qiuling Chen (Автор), Guoshu Chen (Автор), Jixiang He (Автор), Guowei Li (Автор), Jie Zha (Автор), Bing Xu (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2022-10-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Leukemia stem cells (LSCs) constitute the critical barrier to the cure of acute myeloid leukemia (AML) due to their chemoresistance and immune evasion property. Herein, the role of anlotinib, a multiple tyrosine kinase inhibitor, in killing LSCs and regulating chemoresistance and immune evasion was...